TP53 and cancer: A recent study found that mutant p53-mediated upregulation of the mevalonate pathway is both necessary and sufficient for architectural phenotypes in breast cancer (Freed-Pastor et al., 2012), offering a new perspective for the role of the mevalonate pathway in cancer.